Slow and Low Start of a Tacrolimus Once Daily Immunosuppressive Regimen
Status:
Active, not recruiting
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate non-inferiority of an advagraf based
immunosuppressive regimen with slower dose tapering and lower starting dose of Advagraf
compared with a standard Advagraf-based immunosuppressive regimen in de novo renal
transplantation. Non inferiority will be assessed by a combined study endpoint consisting of
the development of biopsy-proven rejection of BANFF class Ia or higher and/or graft loss
and/or patient death within the first six months after renal transplantation.